AstraZeneca PLC (LON:AZN) Investors: Credit Suisse Reconfirms Outperform Rating; Envestnet Asset Management Has Lifted By $3.39 Million Its Iron Mtn New (IRM) Position

Iron Mountain Incorporated (NYSE:IRM) Logo

Envestnet Asset Management Inc increased Iron Mtn Inc New (IRM) stake by 171.76% reported in 2017Q4 SEC filing. Envestnet Asset Management Inc acquired 91,515 shares as Iron Mtn Inc New (IRM)’s stock declined 15.29%. The Envestnet Asset Management Inc holds 144,796 shares with $5.46M value, up from 53,281 last quarter. Iron Mtn Inc New now has $9.81B valuation. The stock increased 0.88% or $0.3 during the last trading session, reaching $34.3. About 1.17M shares traded. Iron Mountain Incorporated (NYSE:IRM) has declined 7.75% since May 4, 2017 and is downtrending. It has underperformed by 19.30% the S&P500.

In analysts note shared with investors on 4 May, Credit Suisse reconfirmed their Outperform rating on AstraZeneca PLC (LON:AZN)‘s stock.

Another recent and important AstraZeneca PLC (LON:AZN) news was published by which published an article titled: “G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR …” on April 16, 2018.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 19 have Buy rating, 3 Sell and 9 Hold. Therefore 61% are positive. AstraZeneca PLC has GBX 7800 highest and GBX 4.57 lowest target. GBX 5152.56’s average target is -1.27% below currents GBX 5219 stock price. AstraZeneca PLC had 629 analyst reports since July 23, 2015 according to SRatingsIntel. Liberum Capital downgraded it to “Hold” rating and GBX 5000 target in Thursday, September 14 report. As per Friday, December 18, the company rating was maintained by JP Morgan. The firm has “Buy” rating by Liberum Capital given on Monday, July 17. As per Wednesday, September 28, the company rating was maintained by Shore Capital. The firm earned “Top Pick” rating on Friday, March 9 by Barclays Capital. The firm earned “Buy” rating on Thursday, February 2 by Liberum Capital. The firm earned “Outperform” rating on Tuesday, November 17 by BNP Paribas. On Wednesday, May 25 the stock rating was maintained by Citigroup with “Buy”. As per Monday, September 25, the company rating was maintained by Shore Capital. As per Monday, November 7, the company rating was maintained by Citigroup.

The stock increased 0.37% or GBX 19 during the last trading session, reaching GBX 5219. About 215,896 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since May 4, 2017 and is . It has underperformed by 11.55% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 66.10 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 22.02 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Envestnet Asset Management Inc decreased Powershares Etf Tr Ii (PXH) stake by 394,743 shares to 37,924 valued at $846,000 in 2017Q4. It also reduced Direxion Shs Etf Tr (FAS) stake by 18,651 shares and now owns 105,276 shares. Analog Devices Inc (NASDAQ:ADI) was reduced too.

Among 6 analysts covering Iron Mountain Incorporated (NYSE:IRM), 3 have Buy rating, 2 Sell and 1 Hold. Therefore 50% are positive. Iron Mountain Incorporated has $46 highest and $27 lowest target. $39.20’s average target is 14.29% above currents $34.3 stock price. Iron Mountain Incorporated had 13 analyst reports since October 9, 2015 according to SRatingsIntel. Deutsche Bank downgraded Iron Mountain Incorporated (NYSE:IRM) on Wednesday, June 7 to “Sell” rating. Robert W. Baird maintained the stock with “Hold” rating in Thursday, August 24 report. The stock has “Buy” rating by Goldman Sachs on Tuesday, March 27. As per Thursday, October 5, the company rating was maintained by Robert W. Baird. Stifel Nicolaus maintained Iron Mountain Incorporated (NYSE:IRM) on Tuesday, February 20 with “Buy” rating. Stifel Nicolaus maintained the shares of IRM in report on Friday, October 20 with “Buy” rating. The stock of Iron Mountain Incorporated (NYSE:IRM) has “Buy” rating given on Friday, July 28 by Stifel Nicolaus. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, February 16 report. Stifel Nicolaus upgraded the shares of IRM in report on Monday, April 18 to “Buy” rating. The rating was maintained by Robert W. Baird on Wednesday, October 25 with “Neutral”.

More important recent Iron Mountain Incorporated (NYSE:IRM) news were published by: which released: “Iron Mountain: Investing In Boxes, Buildings, Or Both?” on April 30, 2018, also published article titled: “Iron Mountain: A Stock For Safe Keeping”, published: “Iron Mountain (IRM) Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. More interesting news about Iron Mountain Incorporated (NYSE:IRM) was released by: and their article: “In Your 60s? 3 Stocks You Should Consider Buying” with publication date: April 30, 2018.

Iron Mountain Incorporated (NYSE:IRM) Ratings Chart